Page 132 - 《中国药房》2022年6期

[10] HECKSL，MECINAJ A，REE AH，et al. Prevention of car- [21] PREMER C，LAMONDIN C，MITZEY A，et al. Immuno-
diac dysfunction during adjuvant breast cancer therapy histochemical localization of AT1a，AT1b，and AT2 angio-
（PRADA）：extended follow-up of a 2 × 2 factorial，ran- tensin Ⅱ receptor subtypes in therat adrenal，pituitary，
domized，placebo-controlled，double-blind clinical trial of and brain with a perspective commentary[J]. Int J Hyper-
candesartan and metoprolol[J]. Circulation，2021，143 tens，2013，2013：175428.
（25）：2431-2440. [22] DE KLOET A D，WANG L，LUDIN J A，et al. Reporter
[11] WITTAYANUKORN S，QIAN JJ，WESTRICK S C，et al. mouse strain provides a novel look at angiotensin type-2
Prevention of trastuzumab and anthracycline-induced car- receptor distribution in the central nervous system[J].
diotoxicity using angiotensin-converting enzyme inhibi- Brain Struct Funct，2016，221（2）：891-912.
tors or β-blockers in older adults with breast cancer[J]. [23] ROLDAN C J，SONG J，ENGLE M P，et al. Angioten-
Am J Clin Oncol，2018，41（9）：909-918. sin-converting enzyme inhibitors and angiotensin receptor
[12] OLORUNDARE O E，ADENEYE A A，AKINSOLA A O， blockers modulate the function of myelinated fibers after
et al. Therapeutic potentials of selected antihypertensive chemotherapy：aquantitative sensory testing study[J]. Pain
agents and their fixed-dose combinations against trastu- Physician，2017，20（4）：281-292.
zumab-mediated cardiotoxicity[J]. Front Pharmacol，2020， [24] KIM E，HWANG S H，KIM H K，et al. Losartan，an angio-
11：610331. tensin Ⅱ type 1 receptor antagonist，alleviates mechanical
[13] AL-HARBI N O，IMAM F，NADEEM A，et al. Protection hyperalgesia in a rat model of chemotherapy-induced neu-
against tacrolimus-induced cardiotoxicity in rats by olme- ropathicpain by inhibiting inflammatory cytokines in the
sartan and aliskiren[J]. Toxicol Mech Methods，2014，24 dorsal root Ganglia[J]. Mol Neurobiol，2019，56（11）：
（9）：697-702. 7408-7419.
[14] RODGERS KE，DIZEREGA G S. Contribution of the lo- [25] BESSAGUET F，DANIGO A，BOUCHENAKI H，et al.
cal RAS to hematopoietic function：anovel therapeutic tar- Neuroprotective effect of angiotensin Ⅱ type 2 receptor
get[J]. Front Endocrinol（Lausanne），2013，4：157. stimulation in vincristine-induced mechanical allody-
[15] KIM S，ZINGLER M，HARRISON J K，et al. Angiotensin nia[J]. Pain，2018，159（12）：2538-2546.
Ⅱ regulation of proliferation，differentiation，and engraft- [26] BESSAGUET F，DANIGO A，MAGY L，et al. Candesar-
ment of hematopoietic stem cells[J]. Hypertension，2016， tan prevents resiniferatoxin-induced sensory small-fiber
67（3）：574-584. neuropathy in mice by promoting angiotensin Ⅱ-mediated
[16] RODGERS K E，ESPINOZA T B，RODA N，et al. Angio- AT2 receptor stimulation[J]. Neuropharmacology，2017，
tensin-（1-7）synergizes with colony-stimulating factors in 126：142-150.
hematopoietic recovery[J]. Cancer Chemother Pharmacol， [27] NIHEI S，SATO J，HARADA T，et al. Antiproteinuric ef-
2013，72（6）：1235-1245. fects of renin-angiotensin inhibitors in lung cancer pa-
[17] PHAM H，SCHWARTZ B M，DELMORE J E，et al. Phar- tients receiving bevacizumab[J]. Cancer Chemother Phar-
macodynamic stimulation of thrombogenesis by angioten- macol，2018，81（6）：1051-1059.
sin（1-7）in recurrent ovarian cancer patients receiving [28] YANG J，YANG X，GAO L，et al. The role of the renin-an-
gemcitabine and platinum-based chemotherapy[J]. Cancer giotensin system inhibitors in malignancy：a review[J].
Chemother Pharmacol，2013，71（4）：965-972. Am J Cancer Res，2021，11（3）：884-897.
[18] RODGERS K E，ESPINOZA T，FELIX J，et al. Accelera- [29] ZHAO Y X，CAO J H，MELAMED A，et al. Losartan
tion of healing，reduction of fibrotic scar，and normaliza- treatment enhances chemotherapy efficacy and reduces as-
tion of tissue architecture by an angiotensin analogue，Nor- cites in ovarian cancer models by normalizing the tumor
Leu3-A（1-7）[J]. PlastReconstr Surg，2003，111（3）： stroma[J]. Proc Natl Acad Sci USA，2019，116（6）：
1195-1206. 2210-2219.
[19] GAFFNEY K，WEINBERG M，SOTO M，et al. Develop- [30] MURPHY J E，WO J Y，RYAN D P，et al. Total neoadju-
ment of angiotensin Ⅱ（1-7）analog as an oral therapeutic vant therapy with FOLFIRINOX in combination with
for the treatment of chemotherapy-induced myelosuppres- losartan followed by chemoradiotherapy for locally ad-
sion[J]. Haematologica，2018，103（12）：e567-e570. vanced pancreatic cancer：a phase 2 clinical trial[J]. JAMA
[20] BALOGH M，AGUILAR C，NGUYEN N T，et al. Angio- Oncol，2019，5（7）：1020-1027.
tensin receptors and neuropathic pain[J]. Pain Rep，2021，6 [31] KASI A，ALLEN J，MEHTA K，et al. Association of losar-
（1）：e869. tan with outcomes in metastatic pancreatic cancer patients

·762 · China Pharmacy 2022 Vol. 33 No. 6 中国药房 2022年第33卷第6期